Liquid-liquid phase separation induces pathogenic tau conformations in vitro.
Kanaan NM, Hamel C, Grabinski T, Combs B. · 2020
Read Liquid-liquid phase separation induces pathogenic tau conformations in vitro. by Kanaan NM, Hamel C, Grabinski T, Combs B. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7272632.txt.
Introduction
Kanaan and co-authors show that when the protein tau gathers into liquid droplets, it can twist into harmful shapes. Their study appeared in Nature Communications. Tau is best known for building up in Alzheimer's disease and related disorders. Like several disease proteins, it can separate out of solution into droplets, a process called liquid-liquid phase separation.
At normal protein levels in lifelike buffers, tau formed dynamic droplets. Disease-linked changes, including the P301L mutation and a disease-associated phosphate pattern, made droplets form more easily and move more slowly. Left longer in this state, tau adopted toxic shapes and clumped into small oligomers rather than fibers. The P301L form produced the most oligomers. Droplet formation, the authors suggest, may be an early step toward disease.
Catalog record
| CREATOR | Kanaan NM, Hamel C, Grabinski T, Combs B. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Liquid-liquid phase separation induces pathogenic tau conformations in vitro By Nicholas M. Kanaan, Chelsey Hamel, Tessa Grabinski, Benjamin Combs Published in: Nature Communications DOI: 10.1038/s41467-020-16580-3 ABSTRACT Formation of membrane-less organelles via liquid-liquid phase separation is one way cells meet the biological requirement for spatiotemporal regulation of cellular components and reactions. Recently, tau, a protein known for its involvement in Alzheimer’s disease and other tauopathies, was found to undergo liquid–liquid phase separation making it one of several proteins associated with neurodegenerative diseases to do so. Here, we demonstrate that tau forms dynamic liquid droplets in vitro at physiological protein levels upon molecular crowding in buffers that resemble physiological conditions. Tau droplet formation is significantly enhanced by disease-associated modifications, including the AT8 phospho-epitope and the P301L tau mutation linked to an inherited tauopathy. Moreover, tau droplet dynamics are significantly reduced by these modified forms of tau. Extended phase separation promoted a time-dependent adoption of toxic conformations and oligomerization, but not filamentous aggregation. P301L tau protein showed the greatest oligomer formation following extended phase separation. These findings suggest that phase separation of tau may facilitate the formation of non-filamentous pathogenic tau conformations. INTRODUCTION Compartmentalization allows for the spatiotemporal separation of biological constituents and reactions, an essential feature of cell biology. Though organelles are typically encapsulated by membranes, an alternative form of molecular organization by which specific biomolecules are localized and concentrated within discrete subcellular regions is the formation of membrane-less organelles1. Nucleoli, stress granules, P granules and Cajal bodies are examples of membrane-less organelles involved in multiple cellular processes including gene regulation, ribosome function and regulation of signal transduction2. These organelles display characteristics of liquid-like structures and are believed to form via a process called liquid–liquid phase separation (LLPS)2. Phase separation into liquid droplet-like structures allows rapid, reversible condensation of specific proteins and nucleic acid molecules into discrete assemblies that dynamically exchange biomolecules with the surrounding cytoplasm and nucleoplasm3–6. Several so-called disordered proteins and other proteins containing low complexity domains are involved in the formation of membrane-less organelles in situ7 and undergo LLPS into liquid droplet structures in vitro8. Formation of membrane-less organelles or LLPS structures has important implications for the normal biological functions and pathological processes that involve these proteins9,10. Tau is a microtubule-associated protein that is traditionally described as “intrinsically disordered” and shares many of the same properties as other proteins that phase separate and are found in membrane-less organelles11. Tau proteins exhibit concentrated regions of charged residues, distributed aromatic (i.e. tyrosine and phenylalanine) and polar amino acids and segments with highly negative or positive overall charges at physiological pH. Moreover, tau is present in membrane-less organelles, including the nucleolus and stress granules where it may serve normal functional roles and potentially pathological roles in disease12–14. Given these characteristics of tau, it is not entirely surprising that multiple studies demonstrate tau phase separation in vitro at physiological and supraphysiological levels under a relatively wide range of experimental conditions15–28, and recent evidence suggest tau may participate in phase separation-like structures and/or stress granules in neurons and other cells14,19,24,29. Some of these studies suggest that the physiological role of tau phase separation may include regulation of RNA, stress granule formation and/or nucleating microtubule polymerization (reviewed in refs. 30,31). Moreover, data suggest tau phase separation is influenced by electrostatic interactions between different subdomains of the protein, the lysine amino acid composition of tau, post-translational modifications of tau (e.g. phosphorylation and acetylation), extension of the polypeptide chain and/or interactions with other proteins (e.g. tubulin and EFhd2) or RNAs15–28. These findings support a potential role for tau as a component of LLPS structures, a hypothesis that would align with the accumulating evidence that tau is more than simply a microtubule stabilizing protein. Tau became infamous for its role in several diseases collectively known as tauopathies, including Alzheimer’s disease (AD) and numerous forms of frontotemporal dementia (e.g. frontotemporal dementia with parkinsonism linked to chromosome 17, FTDP-17)32,33. These diseases are characterized by abnormal and pathogenic changes to tau conformation, oligomerization and aggregation of the protein, as well as increased tau phosphorylation34. Several of these modifications confer toxic properties onto tau. Conformational display of the phosphatase-activating domain (PAD) in the extreme amino terminus35, formation of soluble oligomeric species36 and the presence of the AT8 phosphoepitope37,38 confer toxicity on tau via a mechanism that impairs axonal transport35 and synaptic functions39,40. Mutation of proline 301 to a leucine in tau (P301L) is particularly toxic and causes inherited FTDP-17 in humans41. The processes that drive the transition of tau from a normal monomer to pathological forms remain unknown, as do the factors that modulate tau LLPS and whether tau LLPS generates pathogenic tau species. Here, we show that full-length, wild-type, human tau undergoes LLPS at physiological levels (i.e. 1–2 µM) that is dependent upon the presence of both the N terminus and microtubule-binding domains (MTBRs). We also found that disease-related P301L and AT8 modifications significantly enhance LLPS in vitro. Importantly, we demonstrate that prolonged LLPS leads to reduced droplet dynamics and a time-dependent increase in specific pathogenic conformations and oligomeric tau species that are linked to mechanisms of tau toxicity without the appearance of bona fide tau filaments. Collectively, these data highlight a potential role for tau LLPS in the formation of neurotoxic tau species and provide insights into the effects that disease-related modifications have on tau phase separation in vitro. RESULTS Strategy for studying tau liquid–liquid phase separation A common method for studying LLPS is to either conjugate fluorophores to the protein of interest or to create fluorescent protein fusion constructs. Tau exhibits two well-characterized in vitro behaviors, microtubule binding and aggregation into filaments. Before using fluorescently labeled proteins in LLPS studies, we determined whether fluorescent labels affect microtubule binding and in vitro tau aggregation behavior (Supplementary Methods). We assessed the microtubule-binding ability of recombinant, full-length human tau (tau; 441 amino acids, the hT40 or 2N4R isoform), tau-GFP fusion protein (tau-GFP), Tau labeled with fluorescein isothiocyanate (FITC-tau) or tau labeled with Alexa 568 dye (A568-tau). Binding to microtubules with tau and tau-GFP was robust as evidenced by nearly complete pull-down of tau with microtubules in pelleting assays (Supplementary Fig. 1a, b). In contrast, FITC-tau and A568-tau showed reduced microtubule binding (Supplementary Fig. 1a, b). These data indicate that tau-GFP fusion protein and unlabeled tau bind microtubules similarly, whereas conjugation of fluorescent molecules impedes microtubule binding. We determined whether fluorescent labels affect in vitro aggregation behavior with arachidonic acid induction. Normally, tau forms a mixture of filamentous aggregates and small globular oligomeric aggregates42. As expected, unlabeled tau produced the typical mixture of filaments and globular oligomers, which was nearly identical to the aggregates formed by tau-GFP proteins (Supplementary Fig. 1c). In contrast, FITC-tau and A568-tau produced large clusters of clumped proteins that did not resemble the standard filamentous aggregates formed by arachidonic acid induction (Supplementary Fig. 1c). Both FITC-tau and A568-tau can phase separate into droplet-like structures (Supplementary Fig. 1d, e); however, their impaired microtubule binding and abnormal in vitro aggregation properties raise concern of whether these proteins are appropriate for analysis of tau behavior in vitro. Thus, tau-GFP fusion proteins were used in subsequent LLPS imaging experiments because they exhibit normal microtubule binding and aggregation in vitro, criteria often not employed